Member Info for BOJO2020

Next* excuse phone fingers

Here is an example of what examining the WGS with Mext Generation Sequencing can achieve (only if you have a Parsortix device)

https://www.lse.co.uk/rns/breakthrough-clinical-results-b0km788ah9aflqm.html

Https://www.bbc.co.uk/news/health-67923268

Angle*

Today on BBC news talking about a large study DNA genome sequencing and it's ability to aid cancer treatment. Cor blimey governor that happens to be the exact same area have been working on this last year.

Bantham,

"what happens after we hit the golden cross."

We hit the Red Lion of course

Cheers!

Recent months*

Sang, I am sure you appreciate that the end users have many different ways of working. Angle has had to become better at matching these differing requirements. Hence the "kits" which are much more challenging to develop than "regular assays" and of course Next Generation Sequencing. Angle have informed the market that they have been engaged in all three in recent month. I think it is more of a case that we as investors are beginning to understand what the company has achieved over the last year or so.

Sang,

The Solaris trial has been fully recruited (100 subjects ) as per webinar Sep 23, and presentations since, and the deck of slides that accompany them, and the company website. We are awaiting results which may take some time, depending on which platform is or will be used to present them. Although there is a MHRA link which shows the trial as being terminated due to low recruitment, I am happy with all the multiple evidence that there are 100 subjects that have provided samples and I will wait.

Dont think you are supposed to give a link out on LSE. However people could try the ticker and the primary device on a search and find their own way...

I am in Angle and the share price has had a good rise in the last week. Not quite the levels of OBD mind. I can honestly say at no time did any of us know where the share price was headed and still don't! This is because shares often do better rising on potential than reality. What you are talking about is a valuation based on reality and not potential (as facts become clear of drug utility). Err, I don't know, potential seems to do ok to be honest. IMO.

Hi TGTD,

That is the point. The results of the 47 subjects are scaleable. There really is no reason not to add Parsortix to NGS is there. However this is just one route to market for Parsortix, but it is very direct and straightforward. I agree with Bermuda Shorts, it will take time for everyone to realise what these results actually mean.

ATB

Thanks Bermuda for your view. Very much appreciated. A few of us have made a bit of a leap in understanding today regarding NGS.

I also found this very helpful:

https://youtu.be/WKAUtJQ69n8?si=-DSGOK3gKvO3xZVE

At first I presumed incorrectly that an assay would be used with a third party system as Angle are aiming for with the prostate and ovarian study. But this route seems a lot more direct and an excellent route to market.

As ever with Angle, the devil is in the detail.

ATB

I have left a question for you on the Angle board. If you have a moment could you take a look?

Many Thanks

Wondering if you can help...

Regarding the Illumina NGS results achieved in 47 subjects. Can you confirm my understanding that NGS requires a series of steps rather than an assay (that Angle would either buy of the shelf or develop it's own). Or, do you think it is possible that Angle could/have used an assay in combination. Is that even something that is done? I have asked IG today by email so lets see what he says too. I was rather hoping at first that Angle might have developed it's first molecular assay but I think that is unlikely. Would appreciate your views.

ATB

Good ere init! Hope you are doing well...!

TGTD,

Punching above your weight again. Have to admire your ambition

Yes. Anytime now I would imagine. However the directors refuse to be drawn on whether it will be Ovarian or Prostate first.

2023 Avacta maintained an average share price of £1.25 with 283 million shares in issue.

Scancell sits at 11p with four times as many shares fully diluted (1.2 Billion)

So if you divide £1.25 by four (to give a comparable share issue to Avacta) it gives an average share price of 31p for SCLP.

Or if you times 11p by four you get an Avacta share price of 44p. However as stated, Avacta has been hanging around £1.25 for a year or so, which in my book makes it a fact on which too base a reasonable estimate of where two separate companies with equalled out share capital and prospects should stand

Here we sit at 11p...

Https://www.msn.com/en-gb/health/other/woman-struck-twice-by-tonsil-cancer-celebrates-as-tumour-shrinks-in-half/ar-AA1m7rHL?ocid=socialshare

Probably not us as the timings and size of trial may not be right. Also phase 2 Head and neck. But good to see things working for the patient